 AstraZeneca shares slipped as it reported mixed results from its latest trial PEARL of the cancer drug Imfinzi. Using Imfinzi as a single therapy for lung cancer sufferers, the drug missed its primary endpoint of improving survival rates among patients with stage IV metastatic disease and showing high levels 25 of the biomarker PD-L1. 